The anti-vascular endothelial growth factor (VEGF) antibody bevacizumab (BV) is clinically validated to treat human cancers in adults, and is currently being evaluated as a therapy for pediatric tumors, including neuroblastoma [1]. This evidence concerns the gene VEGFA and cancer.